Oksana Demediuk, MD
Retina Specialist · Augusta, GANPI 1972599496
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (53.6%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 87.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $10,882 and has fallen 96.2% since, to $412 in 2025.
Across 66 payments — averaging $234.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$14K
- Genentech USA, Inc.$502
- Regeneron Healthcare Solutions, Inc.$450
- Astellas Pharma US Inc$344
- Alimera Sciences, Inc.$111
- Biogen$107
- plus $476 from 12 others
What the payments were for
- Food & beverage$1,99013%
- Ownership interest$5,20234%
- Other$8,31554%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $13,516 |
| Genentech USA, Inc. | 18 | $502 |
| Regeneron Healthcare Solutions, Inc. | 10 | $450 |
| Astellas Pharma US Inc | 5 | $344 |
| Alimera Sciences, Inc. | 1 | $111 |
| Biogen | 5 | $107 |
| Kala Pharmaceuticals, Inc. | 3 | $106 |
| Coherus Oncology, Inc. | 3 | $72 |
| Bausch & Lomb Americas Inc. | 3 | $63 |
| Apellis Pharmaceuticals, Inc. | 2 | $40 |
| Sandoz | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Harrow Eye, LLC | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| Novartis | 1 | $20 |
| Eyepoint US, Inc. | 1 | $16 |
| Alcon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 119 | $7,614 |
| Ciprofloxacin Hcl | 395 | $5,234 |
| Dorzolamide Hcl | 210 | $3,972 |
| Cyclosporine | 13 | $3,232 |
| Ketorolac Tromethamine | 107 | $2,914 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 46 | $2,522 |
| Difluprednate | 11 | $1,984 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 89 | $1,661 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,633 |
| Timolol Maleate | 72 | $1,056 |
| Latanoprost | 104 | $973 |
| ErythromycinErythromycin Base | 78 | $770 |
| Brimonidine Tartrate | 22 | $303 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $253 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $187 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Augusta
- Ranjit DhaliwalAugusta$18K
- Sohail KhanAugusta$3K
- Diego Espinosa-HeidmannAugusta$2K
- Julian NussbaumAugusta$891
- David Chin YeeAtlanta$816K
- Daniel OhAtlanta$58K
- Sruthi ArepalliAtlanta$30K
- Alexander BottiniBraselton$7K
- Kareem SioufiMarietta$6K
- James FrankAtlanta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.